CSLLY
CSL Limited
OTC Markets OTCQXUSDEQUITY
DELAYED
Last price
30.26
▼ 0.18 (0.59%)
MARKET · —
Price
Open
30.33
Prev close
30.44
Day high
30.33
Day low
30.13
Volume
19.38K
Market cap
—
P/E (TTM)
—
52W range
16.01 – 36.29
Trailing performance
Returnvs SPY
1W
+25.51%
+26.9%
1M
+50.10%
+46.4%
3M
+69.52%
+66.4%
6M
+12.03%
+1.0%
YTD
+5.07%
-7.2%
1Y
-14.47%
-34.5%
3Y
-30.64%
-104.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
26.35
+14.83% from price
SMA 20
24.30
+24.51% from price
SMA 50
22.00
+37.56% from price
SMA 100
21.47
+40.97% from price
SMA 200
24.93
+21.37% from price
EMA 12
26.55
+13.97% from price
EMA 26
24.44
+23.82% from price
EMA 50
22.96
+31.77% from price
RSI (14)
83.9
Overbought
MACD (12,26,9)
2.11
Hist 0.72
ATR (14)
0.81
2.68% of price
Realised vol 30D
58.0%
Annualised
Bollinger upper
30.13
20, 2σ
Bollinger lower
18.47
20, 2σ
50 / 200 cross
Death
22.00 vs 24.93
Trend bias
Above 200
+21.37%
Risk profile
Beta vs SPY
0.42
Less volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
58.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-54.7%
Peak to trough
Max drawdown 5Y
-72.0%
Peak to trough
ATR 14
0.81
2.68% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
PR Newswire · 26d ago
Australia to challenge Trump’s new 12.5% tariff, says PM Albanese
Investing.com · 28d ago
European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked
The Wall Street Journal · 57d ago
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
CNW Group · 57d ago
Imugene strengthens board with biotech and pharma appointments
Proactive · 89d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.